AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.

A. Ivashchenko; K. Dmitriev; N. Vostokova; V. Azarova; A. Blinow; A. Egorova; I. Gordeev; A. Ilin; R. Karapetian; D. Kravchenko; N. Lomakin; E. Merkulova; N. Papazova; E. Pavlikova; N. Savchuk; E. Simakina; T. Sitdekov; E. Smolyarchuk; E. Tikhomolova; E. Yakubova; A. Ivachtchenko

Статья

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.

A. Ivashchenko, K. Dmitriev, N. Vostokova, V. Azarova, A. Blinow, A. Egorova, I. Gordeev, A. Ilin, R. Karapetian, D. Kravchenko, N. Lomakin, E. Merkulova, N. Papazova, E. Pavlikova, N. Savchuk, E. Simakina, T. Sitdekov, E. Smolyarchuk, E. Tikhomolova, E. Yakubova, A. Ivachtchenko,

2020

https://doi.org/10.1093/cid/ciaa1176

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.

Цитирование

Источник

Версии

1. Version of Record от 2020-08-09

Метаданные

Об авторах

A. Ivashchenko
ChemRar High-Tech Center, Khimki, Moscow region, Russian Federation.
K. Dmitriev
Russian Direct Investment Fund, Moscow, Russian Federation.
N. Vostokova
IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
V. Azarova
IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
A. Blinow
Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
A. Egorova
IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
I. Gordeev
City Clinical Hospital n.a. O.M. Filatov, Moscow, Russian Federation.
A. Ilin
Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
R. Karapetian
Department of Biology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
D. Kravchenko
Department of Chemistry and Technology, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
N. Lomakin
Central Clinical Hospital with Polyclinic, Moscow, Russian Federation.
E. Merkulova
IPHARMA LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
N. Papazova
Department of finished dosage forms, Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
E. Pavlikova
Moscow State University
N. Savchuk
Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.
E. Simakina
Clinical Hospital No.1, Smolensk, Russian Federation.
T. Sitdekov
Russian Direct Investment Fund, Moscow, Russian Federation.
E. Smolyarchuk
I.M. Sechenov First Moscow State Medical University
E. Tikhomolova
Infectious clinical hospital No. 2, Nizhny Novgorod, Russian Federation.
E. Yakubova
Chromis LLC, Skolkovo Innovative Centre, Moscow, Russian Federation.
A. Ivachtchenko
Chemical Diversity Research Institute, Khimki, Moscow region, Russian Federation.

Предметная рубрика

COVID-19

Название журнала

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Ключевые слова

AVIFAVIR;COVID-19;SARS-CoV-2;favipiravir;

Тип документа

journal article

Тип лицензии Creative Commons

CC BY-NC-ND

Правовой статус документа

Свободная лицензия

Источник

lens

Поиск по репозиторию

Статья

AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.

Похожие публикации

Источник

Версии

Метаданные